Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
boniva
Synonyms :
Class :
Calcium metabolism modifiers, Biphosphonate derivative
Brand Name :
boniva
Synonyms :
Class :
Calcium metabolism modifiers, Biphosphonate derivative
Dosage Forms & StrengthsÂ
Tablet:150mgÂ
Prefilled syringe:1mg/1mlÂ
150
mg
Tablet
Orally 
once a month
IV:3 mg every 3 months
It may decrease the effects of human parathyroid hormone
gilteritinib may enhance the QTc-prolonging effect of QT-prolonging Agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may diminish the serum concentration of polyvalent cation-containing products
may increase the QTc prolonging effect
may increase the QTc prolonging effect
may have an increased QTc-prolonging effect when combined with amisulpride (oral)
may increase the QTc prolonging effect of QT-prolonging agents
may have an increased QTc-prolonging effect when combined with amiodarone
may have an increased QTc-prolonging effect when combined with delamanid
may diminish the serum concentration of Polyvalent Cation Containing Products
aluminum hydroxide/magnesium carbonateÂ
may decrease the serum concentration of Polyvalent Cation Containing Products
may decrease the serum concentration of Polyvalent Cation Containing Products
dasatinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
encorafenib: they may increase the QTc-prolonging effect of QTc-prolonging agents
etelcalcetide: they may increase the QTc-prolonging effect of QTc-prolonging agents
flecainide: they may increase the QTc-prolonging effect of QTc-prolonging Agents
fluconazole: they may increase the QTc-prolonging effect of QTc-prolonging agents
methadone: they may increase the QTc-prolonging effect of QTc -prolonging agents
sunitinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
regenerative and osteoconductive effects of hydroxyapatite may be enhanced when administered with bisphosphonates
dapagliflozin: it may increase the risk or severity of QTc prolongation
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may increase GI bleeding, ulceration and irritation
may increase GI bleeding, ulceration and irritation
may increase GI bleeding, ulceration and irritation
it may enhance the QTc-prolonging effect of terfenadine
may diminish the serum concentration of polyvalent cation-containing products
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with pazopanib
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
clarithromycin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
levoketoconazole: they may increase the QTc-prolonging effect of QTc-prolonging Agents
probucol: they may increase the QTc-prolonging effect of QTc-prolonging Agents
sparfloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
the QTc-prolonging effect of citalopram can be increased with QT-prolonging agents
angiogenesis Inhibitors may enhance the adverse/toxic effect of bisphosphonate derivatives
angiogenesis Inhibitors may enhance the adverse/toxic effect of bisphosphonate derivatives
angiogenesis Inhibitors may enhance the adverse/toxic effect of bisphosphonate derivatives
angiogenesis Inhibitors may enhance the adverse/toxic effect of bisphosphonate derivatives
angiogenesis Inhibitors may enhance the adverse/toxic effect of bisphosphonate derivatives
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of cation binding in the GI tract
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of cation binding in the GI tract
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
when combined, Bisphosphonate Derivative's side effects can be increased with NSAIDs
when combined, Bisphosphonate Derivative's side effects can be increased with NSAIDs
when combined, Bisphosphonate Derivative's side effects can be increased with NSAIDs
when combined, Bisphosphonate Derivative's side effects can be increased with NSAIDs
when combined, Bisphosphonate Derivative's side effects can be increased with NSAIDs
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increased QTc-prolonged effect when combined with chloroquine
may have an increased QTc-prolonged effect when combined with chloroquine
May enhance the toxic effects of the other by pharmacodynamic synergism
May enhance the toxic effects of the other by pharmacodynamic synergism
NSAIDs may enhance the adverse/toxic effect of Bisphosphonate Derivatives
NSAIDs may enhance the adverse/toxic effect of Bisphosphonate Derivatives
NSAIDs may enhance the adverse/toxic effect of Bisphosphonate Derivatives
NSAIDs may enhance the adverse/toxic effect of Bisphosphonate Derivatives
NSAIDs may enhance the adverse/toxic effect of Bisphosphonate Derivatives
NSAIDs increase the toxicity of bisphosphonate derivatives
NSAIDs increase the toxicity of bisphosphonate derivatives
NSAIDs increase the toxicity of bisphosphonate derivatives
NSAIDs increase the toxicity of bisphosphonate derivatives
NSAIDs increase the toxicity of bisphosphonate derivatives
they increase the effect of hypocalcemia in bisphosphonate derivatives
they increase the effect of hypocalcemia in bisphosphonate derivatives
they increase the effect of hypocalcemia in bisphosphonate derivatives
they increase the effect of hypocalcemia in bisphosphonate derivatives
they increase the effect of hypocalcemia in bisphosphonate derivatives
they increase the toxicity of bisphosphonate derivatives
they increase the toxicity of bisphosphonate derivatives
they increase the toxicity of bisphosphonate derivatives
they increase the toxicity of bisphosphonate derivatives
they increase the toxicity of bisphosphonate derivatives
bisphosphonate derivatives increase the toxicity of deferasirox
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the adverse/toxic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the Qtc prolonging effect
may enhance the hypocalcemic effect of bisphosphonate derivatives
may enhance the hypocalcemic effect of bisphosphonate derivatives
may enhance the hypocalcemic effect of bisphosphonate derivatives
may enhance the hypocalcemic effect of bisphosphonate derivatives
may enhance the hypocalcemic effect of bisphosphonate derivatives
may enhance the risk of adverse effect of bisphosphonate derivatives
may enhance the risk of adverse effect of bisphosphonate derivatives
may enhance the risk of adverse effect of bisphosphonate derivatives
may enhance the risk of adverse effect of bisphosphonate derivatives
may enhance the risk of adverse effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
may increase the hypo calcaemic effect
may decrease the serum concentration and decrease in the efficacy
may increase the toxic effect of non-steroidal anti-inflammatory drugs
may increase the QTc prolonging effect of QTc prolonging agents
may have an increased QTc-prolonging effect when combined with haloperidol
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of angiogenesis inhibitors
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
neomycin/polymyxin B/bacitracin topical
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
aminoglycosides increase the effect of hypocalcemia of bisphosphonate derivatives
may have an increased QTc-prolonging effect when combined with chloroquine
may have an increased QTc-prolonging effect when combined with gadobenate dimeglumine
It may increase the nephrotoxic effect when combined with Bisphosphonate Derivatives
It may increase the toxic effect when combined with Bisphosphonate Derivatives
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
fingolimod: they may increase the QTc-prolonging effect of QT-prolonging Agents
It may enhance the risk of adverse effects when combined with Phosphodiesterase inhibitors
the : QTc-prolonging effect of hydroxyzine can be increased with QT-prolonging agents
may have an increasingly adverse effect when combined with bisphosphonate derivatives
the risk of anti-angiogenesis and jaw osteoporosis may be increased
cetirizine: it may increase the risk or severity of QTc prolongation
atropine: it may increase the risk or severity of QTc prolongation
May enhance the toxic effects of the other by pharmacodynamic synergism
May enhance the toxic effects of the other by pharmacodynamic synergism
may have an increasingly adverse effect when combined with bisphosphonate derivatives
benorilate: it may increase the risk or severity of QTc prolongation agents
cabergoline: it may increase the risk or severity of QTc prolongation agents
canagliflozin: it may increase the risk or severity of QTc prolongation agents
candesartan cilexetil: it may increase the risk or severity of QTc prolongation agents
may increase the effect of each other by decreasing renal clearance
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of domperidone
Frequency defined:Â Â
>10%Â
URI (34%)Â
Back pain (14%)Â
Dyspepsia (12%)Â
Bronchitis (10%)Â
1-10% (selected)Â
AstheniaÂ
DiarrheaÂ
DizzinessÂ
MyalgiaÂ
PneumoniaÂ
Tooth disorderÂ
UTIÂ Â
Post-marketing reportÂ
HypersensitivityÂ
HypocalcemiaÂ
Pregnancy consideration: The drug is not recommended during pregnancyÂ
Pregnancy category: CÂ
Lactation: The excretion of the drug in human breast milk is unknown Â
Pregnancy category:Â
Patient information leafletÂ
Generic Name: ibandronateÂ
Pronounced: i ban’ droh nateÂ
Why do we use ibandronate?Â
Ibandronate is used to treat osteoporosis in postmenopausal women; it also increases bone density and prevents bone breakdown.Â
Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
